english.prescrire.org > Prescrire Awards > The Prescrire Awards for 2011 > The 2011 Prescrire Awards: granted in total independence by Prescrire's Editorial Staff > Prescrire's review of new drugs and new indications in 2011 > Prescrire's ratings over 10 years

The Prescrire Awards for 2011

The 2011 Prescrire Awards: granted in total independence by Prescrire's Editorial Staff

Prescrire's review of new drugs and new indications in 2011
Prescrire's ratings of new products and indications over the last 10 years

Prescrire's ratings of new products and indications over the last 10 years (a)
PRESCRIRE'S RATING
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
 Bravo 0 0 0 0 1 1 0 0 0 0
 A real advance 4 4 0 1 1 2 0 0 1 0
 Offers an advantage 9 5 6 4 8 14 6 3 3 3 (c)
 Possibly helpful 18 23 12 20 31 27 25 14 22 13
 Nothing new
35 34 41 38 69 79 57 62 49 53
 Not acceptable
6 (b) 7 (b) 7 19 17 15 23 19 19 16 (d)
 Judgement reserved
0 6 4 2 8 3 9 6 3 7 (e)
    Total 72 79 4 84 135 141 120 104 97 92
 
Notes :
a - For reasons of space, this table only shows the results for the last 10 years. The previous years’ results (1981 to 2001) can be found in Prescrire Int n°58. This table shows new products (other than generics copies) and new indications proposed by drug companies to physicians and pharmacists, for use in hospitals and/or the community; and, from 2005 onwards, line extensions (new dose strengths, new form/presentations of existing drugs) and products for self-medication, rated in our French edition la revue Prescrire. A given product is counted several times if it was rated differently in its different indications.
b - Including two jointly marketed products.
c - The drugs were:
  • collagenase clostridium histolyticum in Dupuytren’s contracture (Prescrire Int n° 122);
  • mesalazine in ulcerative colitis and Crohn’s disease in children (Prescrire Int n° 119);
  • tocofersolan in vitamin E deficiency (Rev Prescrire n° 333).
d - The drugs were:
  • aciclovir + hydrocortisone in herpes labialis (Prescrire Int n° 119);
  • bendamustine in second line therapy of indolent non-Hodgkin's lymphomas and multiple myeloma (Rev Pres­crire n° 338);
  • bleomycin in malignant pleural effusion (Prescrire Int n° 122);
  • denosumab in postmenopausal osteoporosis (Prescrire Int n° 117);
  • denosumab in prostate cancer related bone loss (Rev Prescrire n° 329);
  • docetaxel in adjuvant therapy for breast cancer (Prescrire Int n° 117);
  • erlotinib in maintenance therapy of non-small cell lung cancer (Prescrire Int n° 120);
  • exenatide in type 2 diabetes in combination with glitazones (Rev Prescrire n° 328);
  • fampridine in multiple sclerosis and walking disorder (Rev Prescrire n° 337);
  • lanthane with more follow-up in dialysis patients with chronic kidney failure (Rev Prescrire n° 329);
  • lanthane in non-dialysis patients with chronic kidney failure (Rev Prescrire n° 329);
  • methotrexate 10 mg, a strong dosage in rhumatology (Rev Prescrire n° 331);
  • moxifloxacin in community acquired pneumonia and skin infections (Rev Prescrire n° 327 + 328);
  • omalizumab, a weak dosage in severe persistent asthma (Prescrire Int n° 121);
  • prucalopride in women with chronic constipation (Prescrire Int n° 116);
  • botulinum toxin type A for migraine (Prescrire Int n° 122).
e - The drugs include:
  • abatacept in juvenile idiopathic arthritis (Rev Prescrire n° 328);
  • alglucosidase alfa in late Pompe disease (Rev Prescrire n° 336);
  • bevacizumab off-label in age-related macular oedema (Rev Prescrire n° 331);
  • cabazitaxel in advanced prostate cancer (Prescrire Int n° 123);
  • quetiapine (Xeroquel LP°) in prevention of depression in bipolar disorder (Prescrire Int n° 121);
  • rituximab in maintenance treatment of follicular lymphoma (Rev Prescrire n° 338);
  • sunitinib in pancreatic neuroendocrine tumours (Rev Prescrire n° 337).
©Prescrire April 2012
"New drugs and new indications in 2011. France is better focused on patients' interests after the Mediator° scandal, but stagnation elsewhere" Prescrire Int 2012; 21 (126): 106-110. (pdf, free)
> Return to Prescrire's review of new drugs and new indications in 2011